Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Rectal Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Drug-Related Side Effects and Adverse Reactions 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 17Paclitaxel 16Radiotherapy 10Taxes 9Cisplatin 8Radiation 7Docetaxel 7Gemcitabine 6Gefitinib 6Bevacizumab 6Erlotinib Hydrochloride 5Radiotherapy, Conformal 3Platinum 3Etoposide 31,2-diaminocyclohexaneplatinum II citrate 3methoxyamine 2Vinorelbine 2Tirapazamine 2Pemetrexed 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Disulfides 2Cetuximab 2Bortezomib 2veliparib 1vandetanib 1shark cartilage extract 1pembrolizumab 1pegylated granulocyte colony-stimulating factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma of Lung × Folic Acid × Clear all
NCT00033722 2014-01-06

Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡